Clinical Trial Update: Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

This is a Phase 2 adjuvant trial evaluating dynamic biomarker–adjusted personalized therapy to optimize risk assessment and therapy response prediction in early…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Snippet

Sponsor: West German Study Group | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED